SCHEMBL485174

SCHEMBL485174

O=C1CCC2(CC1)CCN(C(=O)O)CC2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.39
MGLL Q99685 1/20 0.36
CYP3A4 P08684 5/20 0.36
CYP2C19 P33261 5/20 0.36
ALDH1A1 P00352 5/20 0.36
CYP2C9 P11712 5/20 0.36
CYP2D6 P10635 4/20 0.36
MAPK1 P28482 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 3/20 0.35
TSHR P16473 3/20 0.35
CHRM2 P08172 1/20 0.35
CHRM3 P20309 1/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16835521 0.88 MGLL (0.43) MGLLCYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL16835509 0.88 MGLL (0.35) USP2MGLLCYP3A4CYP2C19ALDH1A1
SCHEMBL933548 0.82 USP2 (0.41) USP2CYP3A4CYP2C19ALDH1A1CYP2C9
SCHEMBL16835471 0.81 MGLL (0.39) USP2MGLLCYP3A4CYP2C19ALDH1A1
SCHEMBL23859695 0.81 MGLL (0.34) MGLLCYP3A4CYP2C19ALDH1A1CYP2C9
SCHEMBL15655085 0.81 USP2 (0.36) USP2CYP3A4CYP2C19ALDH1A1CYP2C9
SCHEMBL751237 0.78 USP2 (0.39) USP2CYP3A4CYP2C19ALDH1A1CYP2C9
SCHEMBL3924590 0.78 HSD11B1 (0.42) USP2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL21273908 0.78 CYP3A4 (0.35) USP2MGLLCYP3A4CYP2C19ALDH1A1
SCHEMBL18263256 0.77 GRM5 (0.44) USP2MGLLCYP3A4CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024119278-A1 BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2024-06-13 WO disclosed
WO-2024026256-A1 SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 CELGENE CORPORATION (US) 2024-02-01 WO disclosed
US-20230192655-A1 INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-06-22 US disclosed
EP-4182299-A2 CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 Merck Sharp & Dohme LLC (US) 2023-05-24 EP disclosed
WO-2022228547-A1 PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF 四川海思科制药有限公司 2022-11-03 WO disclosed
WO-2022088551-A1 INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海领泰生物医药科技有限公司 2022-05-05 WO disclosed
WO-2022028547-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海领泰生物医药科技有限公司 2022-02-10 WO disclosed
WO-2022013408-A2 CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 MERCK SHARP & DOHME CORP. (US) 2022-01-20 WO disclosed
US-20200308139-A1 OXOPIPERAZINE DERIVATIVES Inthera Bioscience AG (CH) 2020-10-01 US disclosed
EP-3525790-A2 PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE Merck Sharp & Dohme Corp. (US) 2019-08-21 EP disclosed
US-20100113417-A1 Substituted Spiroamine Compounds GRUENENTHAL GMBH (DE) 2010-05-06 US disclosed
WO-2010049146-A1 SUBSTITUTED SPIROAMINES Grünenthal GmbH (DE) 2010-05-06 WO disclosed
WO-2010046109-A1 PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN Grünenthal GmbH (DE) 2010-04-29 WO disclosed
WO-2009108827-A1 FUSED TRICYCLIC PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF WYETH (US) 2009-09-03 WO disclosed
US-7439263-B2 Pyrrolidine and thiazolidine compounds LES LABORATOIRES SERVIER (FR) 2008-10-21 US disclosed
EP-1899303-A1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-03-19 EP disclosed
EP-1598350-B1 Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis SERVIER LAB (FR) 2007-07-11 EP disclosed
WO-2007000465-A1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO disclosed
US-20050261501-A1 Pyrrolidine and thiazolidine compounds LES LABORATOIRES SERVIER (FR) 2005-11-24 US disclosed
EP-1598350-A1 Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis LES LABORATOIRES SERVIER (FR) 2005-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261501-A1 Pyrrolidine and thiazolidine compounds DPP4, DPP3, NR4A1 USP2 3375/4885MGLL 4780/4885CYP3A4 47/4885
US-20100113417-A1 Substituted Spiroamine Compounds BDKRB1, BDKRB2, REN USP2 4868/4885MGLL 4379/4885CYP3A4 1642/4885
US-20230192655-A1 INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK1, IRAK2 USP2 1587/4885MGLL 3582/4885CYP3A4 69/4885
US-20200308139-A1 OXOPIPERAZINE DERIVATIVES CYP3A5, AQP1, AVPR2 USP2 3518/4885MGLL 4715/4885CYP3A4 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.